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ABSTRACT
Objective We studied evolving antithrombotic therapy
patterns in patients with newly diagnosed non-valvular
atrial ﬁbrillation (AF) and ≥1 additional stroke risk factor
between 2010 and 2015.
Methods 39 670 patients were prospectively enrolled
in four sequential cohorts in the Global Anticoagulant
Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF):
cohort C1 (2010–2011), n=5500; C2 (2011–2013),
n=11 662; C3 (2013–2014), n=11 462; C4 (2014–
2015), n=11 046. Baseline characteristics and
antithrombotic therapy initiated at diagnosis were
analysed by cohort.
Results Baseline characteristics were similar across
cohorts. Median CHA2DS2-VASc (cardiac failure,
hypertension, age ≥75 (doubled), diabetes, stroke
(doubled)-vascular disease, age 65–74 and sex category
(female)) score was 3 in all four cohorts. From C1 to C4,
the proportion of patients on anticoagulant (AC) therapy
increased by almost 15% (C1 57.4%; C4 71.1%). Use
of vitamin K antagonist (VKA)±antiplatelet (AP) (C1
53.2%; C4 34.0%) and AP monotherapy (C1 30.2%;
C4 16.6%) declined, while use of non-VKA oral ACs
(NOACs)±AP increased (C1 4.2%; C4 37.0%). Most
CHA2DS2-VASc ≥2 patients received AC, and this
proportion increased over time, largely driven by NOAC
prescribing. NOACs were more frequently prescribed than
VKAs in men, the elderly, patients of Asian ethnicity,
those with dementia, or those using non-steroidal anti-
inﬂammatory drugs, and current smokers. VKA use was
more common in patients with cardiac, vascular, or renal
comorbidities.
Conclusions Since NOACs were introduced, there has
been an increase in newly diagnosed patients with AF at
risk of stroke receiving guideline-recommended therapy,
predominantly driven by increased use of NOACs and
reduced use of VKA±AP or AP alone.
Trial registration number NCT01090362; Pre-results.
INTRODUCTION
Atrial ﬁbrillation (AF) is associated with a ﬁvefold
increase in stroke risk.1 Strokes associated with AF
have a poorer prognosis compared with non-AF
stroke.2 Evidence-based guidelines for stroke pre-
vention in AF recommend anticoagulant (AC)
therapy for patients with additional stroke risk
factors,3–5 but AC therapy is underused in eligible
patients.6 Furthermore, data from registries suggest
that AC therapy is underused in patients at high
stroke risk and potentially overused in those at low
stroke risk.7–11
The most recent European and North American
guidelines for the management of AF incorporate
recommendations on using non-vitamin K antago-
nist oral ACs (NOACs) as an alternative to vitamin
K antagonists (VKAs).3–5 In the present study, the
evolving patterns of antithrombotic therapy were
investigated using data from a large, prospective,
global cohort study of patients with newly diag-
nosed non-valvular AF in different countries, geo-
graphic regions, care settings, and in patients at
different levels of stroke and bleeding risks.
METHODS
Study design and participants
The Global Anticoagulant Registry in the
FIELD-Atrial Fibrillation (GARFIELD-AF) is an
ongoing, prospective, observational, worldwide
study of adults with recently diagnosed non-
valvular AF from 1215 sites in 35 countries. The
study design has been described previously.12
Brieﬂy, men and women aged ≥18 years with non-
valvular AF diagnosed according to standard local
procedures within the previous 6 weeks and ≥1
additional risk factor for stroke as judged by the
investigator are eligible. These risk factors are not
prespeciﬁed in the protocol, nor are they limited to
the components of existing risk stratiﬁcation
schemes. Patients with a transient reversible cause
of AF and those for whom follow-up is not envi-
saged or possible are excluded. Enrolment takes
place in ﬁve independent, sequential cohorts. To
minimise recruitment bias, investigator sites were
selected randomly from representative care settings
in each participating country and consecutive
patients were enrolled. Sample size calculations are
based on the 95% conﬁdence intervals for estimates
of each of the registry endpoints.12
This paper reports cross-sectional data at baseline
including treatment patterns before and after the
introduction of NOACs, for cohorts 1–4 (cohort 1:
March 2010 to October 2011; cohort 2: August
2011 to June 2013; cohort 3: April 2013 to
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October 2014; cohort 4: March 2014 to July 2015), and has
been written according to the STROBE (Strengthening the
Reporting of Observational Studies in Epidemiology) statement.
Data collection
The electronic case report form (eCRF) was designed by
Dendrite Clinical Systems Ltd (Henley-on-Thames, UK).
Oversight of operations and data management was conducted
by the sponsor and coordinating centre (Thrombosis Research
Institute—TRI, London, UK), with support from Quintiles
(Durham, North Carolina, USA), The University of Birmingham
Department of Primary Care Clinical Sciences (Birmingham,
UK), Thrombosis Research Group—Brigham and Women’s
Hospital (Boston, Massachusetts, USA), and AIXIAL (Paris,
France). The GARFIELD-AF protocol requires source data veri-
ﬁcation of 20% of eCRFs, an electronic audit trail for all data
modiﬁcations, and additional audit of critical variables.12 Data
for the analysis in this report were extracted from the study
database on 3 August 2015.
Deﬁnitions
The term AC includes VKAs and NOACs. The term NOAC
includes oral direct factor Xa inhibitors (FXaIs) and oral direct
thrombin inhibitors (DTIs). Vascular disease was deﬁned as
peripheral artery disease and/or coronary artery disease (CAD)
with a history of acute coronary syndromes. Hypertension was
deﬁned as a documented history of hypertension or blood pres-
sure >140/90 mm Hg. Chronic kidney disease (CKD) was
classiﬁed according to the National Kidney Foundation’s Kidney
Disease Outcomes Quality Initiative (NKF KDOQI) guide-
lines:13 moderate-to-severe includes stages III to V; none or
mild includes all other patients. Congestive heart failure (CHF)
was deﬁned as a history of CHF for patients in cohorts C1 and
C2; from C3 onwards there was a protocol amendment and in
these cohorts, CHF consists of current or prior history of CHF.
Figure 1 Antithrombotic treatment at diagnosis by cohort. The total
population represented by n excludes unknowns. AP, antiplatelet; DTI,
direct thrombin inhibitor; FXaI, factor Xa inhibitor; VKA, vitamin K
antagonist.
Table 1 Baseline characteristics of patients in cohorts 1 to 4
Variable
Cohort 1
2010–2011
(n=5500)
Cohort 2
2011–2013
(n=11 662)
Cohort 3
2013–2014
(n=11 462)
Cohort 4
2014–2015
(n=11 046)
Female, n/N (%) 2402/5500 (43.7) 5116/11 662 (43.9) 5191/11 462 (45.3) 4870/11 046 (44.1)
Age at diagnosis, years, mean (SD) 69.8 (11.5) 69.8 (11.4) 69.6 (11.4)a 69.6 (11.7)
Ethnicity, n/N (%)
Caucasian/Hispanic/Latino 3691/5500 (67.1) 8647/11 662 (74.1) 7896/11 462 (68.9) 7050/11 046 (63.8)
Asian 1589/5500 (28.8) 2392/11 662 (20.5) 3175/11 462 (27.7) 3574/11 046 (32.4)
Other 68/5500 (1.2) 244/11 662 (2.1) 147/11 462 (1.3) 239/11 046 (2.2)
Unwilling to declare 152/5500 (2.8) 379/11 662 (3.2) 244/11 462 (2.1) 183/11 046 (1.7)
Medical history, n/N (%)
CHF 1026/5498 (18.7) 2506/11 662 (21.5) 2206/11 462 (19.2) 2128/11 046 (19.3)
CAD 1059/5498 (19.3) 2357/11 662 (20.2) 2495/11 462 (21.8) 2428/11 046 (22.0)
ACS 553/5498 (10.1) 1061/11 659 (9.1) 1258/11 257 (11.2) 1281/10 884 (11.8)
Vascular disease 847/5498 (15.4) 1653/11 662 (14.2) 1828/11 462 (15.9) 1789/11 046 (16.2)
Systemic embolism 35/5498 (0.6) 74/11 652 (0.6) 85/11 383 (0.7) 78/10 981 (0.7)
Stroke/TIA 727/5498 (13.2) 1459/11 662 (12.5) 1236/11 462 (10.8) 1219/11 046 (11.0)
Bleeding 172/5498 (3.1) 325/11 651 (2.8) 283/11 400 (2.5) 262/10 995 (2.4)
History of hypertension 4224/5498 (76.8) 9172/11 662 (78.6) 8761/11 419 (76.7) 8224/11 004 (74.7)
Diabetes mellitus 1215/5498 (22.1) 2535/11 662 (21.7) 2457/11 462 (21.4) 2443/11 046 (22.1)
Moderate-to-severe CKD* 495/5497 (9.0) 1265/11 662 (10.8) 1209/11 462 (10.5) 1104/11 045 (10.0)
Risk scores
CHA2DS2-VASc, median (Q1–Q3) 3 (2–4)
b 3 (2–4)c 3 (2–4)d 3 (2–4)e
CHA2DS2-VASc, 0–1, n/N (%) 815/5406 (15.1) 1531/11 293 (13.6) 1666/11 252 (14.8) 1700/10 830 (15.7)
HAS-BLED, median (Q1–Q3)† 1 (1–2)f 1 (1–2)g 1 (1–2)h 1 (1–2)i
HAS-BLED, 0–2, n/N (%)† 3109/3561 (87.3) 6321/7302 (86.6) 7650/8584 (89.1) 7824/8654 (90.4)
a1 patient missing; b94 patients missing; c369 patients missing; d210 patients missing; e216 patients missing; f1939 patients missing; g4360 patients missing; h2878 patients missing;
i2392 patients missing.
ACS, acute coronary syndrome; CAD, coronary artery disease; CHA2DS2-VASc, cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65–74
and sex category (female); CHF, congestive heart failure; CKD, chronic kidney disease; NKF KDOQI, National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative; TIA,
transient ischaemic attack.
*Includes NKF KDOQI stages III–V.
†‘modified’ HAS-BLED, hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, elderly (>65), drugs/alcohol concomitantly (1 point each).
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Table 2 Baseline characteristics of patients in cohort 1 to cohort 4 by antithrombotic treatment type
Variable None AP alone AC+AP or AP alone AC+AP NOAC+AP VKA+AP AC±AP NOAC alone VKA alone
N 4802 8714 14 309 5595 1656 3939 25 680 7244 12 841
Female, n (%) 2135 (44.5) 3774 (43.3) 5957 (41.6) 2183 (39.0) 656 (39.6) 1527 (38.8) 11 449 (44.6) 3267 (45.1) 5999 (46.7)
Age at diagnosis, years, mean (SD) 66.8 (13.5) 68.7 (12.1)a 69.4 (11.5)a 70.5 (10.4) 71.2 (10.5) 70.3 (10.3) 70.6 (10.7) 70.7 (10.9) 70.6 (10.8)
Medical history, n (%)
CAD 494 (10.3)b 2834 (32.5) 5139 (35.9) 2305 (41.2) 708 (42.8) 1597 (40.5) 4883 (19.0) 857 (11.8) 1721 (13.4)
Vascular disease 358 (7.5)b 1865 (21.4) 3628 (25.4) 1763 (31.5) 532 (32.1) 1231 (31.3) 3810 (14.8) 682 (9.4) 1365 (10.6)
Systemic embolism 14 (0.3)b 34 (0.4) 96 (0.7) 62 (1.1) 19 (1.2) 43 (1.1) 216 (0.8) 39 (0.5) 115 (0.9)
Stroke 202 (4.2)b 665 (7.7) 1316 (9.2) 651 (11.7) 178 (10.8) 473 (12.0) 2162 (8.4) 508 (7.0) 1003 (7.8)
Bleeding 221 (4.6)b 301 (3.5) 438 (3.1) 137 (2.5) 37 (2.2) 100 (2.5) 492 (1.9) 150 (2.1) 205 (1.6)
Hypertension 3439 (71.6)b 7007 (80.4) 11 787 (82.4) 4780 (85.4) 1403 (84.7) 3377 (85.7) 21 345 (83.1) 5831 (80.5) 10 734 (83.6)
Diabetes mellitus 831 (17.3)b 1816 (20.8) 3533 (24.7) 1717 (30.7) 492 (29.7) 1225 (31.1) 5884 (22.9) 1354 (18.7) 2813 (21.9)
Moderate-to-severe CKD* 371 (7.7)b 826 (9.5)a 1581 (11.0)a 755 (13.5) 208 (12.6) 547 (13.9) 2818 (11.0)a 677 (9.3) 1386 (10.8)a
Risk scores
CHA2DS2-VASc, median (Q1–Q3) 3.0 (1.0–4.0)
c 3.0 (2.0–4.0)d 3.0 (2.0–4.0)e 4.0 (3.0–5.0)f 4.0 (3.0–5.0)g 4.0 (3.0–5.0)h 3.0 (2.0–4.0)i 3.0 (2.0–4.0)j 3.0 (2.0–4.0)k
CHA2DS2-VASc, 0–1, n (%) 1212 (26.5) 1457 (17.1) 1902 (13.5) 445 (8.1) 137 (8.3) 308 (7.9) 2988 (11.9) 1079 (15.1) 1464 (11.7)
HAS-BLED, median (Q1–Q3)† 1.0 (0.0–1.0)l 2.0 (1.0–2.0)m 2.0 (1.0–2.0)n 2.0 (2.0–3.0)o 2.0 (2.0–2.0)p 2.0 (1.0–3.0)q 1.0 (1.0–2.0)r 1.0 (1.0–2.0)s 1.0 (1.0–2.0)t
HAS-BLED, 0–2, n (%)† 2984 (94.2) 4742 (80.0) 7718 (78.0) 2976 (75.0) 911 (76.2) 2065 (74.5) 16 865 (90.4) 5271 (95.0) 8618 (94.4)
a1 patient missing; b2 patients missing; c225 patients missing; d175 patients missing; e244 patients missing; f69 patients missing; g15 patients missing; h54 patients missing; i481 patients missing; j116 patients missing; k296 patients missing; l1634
patients missing; m2787 patients missing; n4413 patients missing; o1626 patients missing; p460 patients missing; q1166 patients missing; r7032 patients missing; s1697 patients missing; t3709 patients missing.
AC, anticoagulant; AP, antiplatelet; CAD, coronary artery disease; CHA2DS2-VASc, cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65–74 and sex category (female); CKD, chronic kidney disease; NKF
KDOQI, National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist.
*Includes NKF KDOQI stages III–V.
†‘modified’ HAS-BLED, hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, elderly (>65), drugs/alcohol concomitantly (1 point each).
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Ethics statement
Independent ethics committee and hospital-based institutional
review board approvals were obtained, as necessary, for the
registry protocol. The registry is being performed in accordance
with the principles of the Declaration of Helsinki, local regula-
tory requirements, and the International Conference on
Harmonisation–Good Pharmacoepidemiological and Clinical
Practice guidelines. All patients gave written informed consent
to participate.
Statistical analysis
The analysis provides descriptive statistics to summarise data
patterns. Continuous variables are expressed as mean±SD and
categorical variables as frequency and percentage. Treatment
patterns were analysed by cohort, by cohort and
CHA2DS2-VASc (cardiac failure, hypertension, age ≥75
(doubled), diabetes, stroke (doubled)-vascular disease, age
65–74 and sex category (female)) score,14 and by cohort and
‘modiﬁed’ HAS-BLED (hypertension, abnormal renal/liver func-
tion (1 point each), stroke, bleeding history or predisposition,
labile international normalised ratios, elderly (>65), drugs/
alcohol concomitantly (1 point each)) score15 (ﬂuctuations in
international normalised ratios were not collected). The risk
scores were calculated retrospectively. NOAC use (relative to
VKA) was analysed according to patient characteristics,
comorbidities, and cohort. Patients in cohorts C2, C3, and C4
using VKA or NOACs were included in the analysis. We
removed patients in C1, since NOACs were not globally avail-
able during this time period. Adjusted odds ratios were esti-
mated using a logistic model based on the following variables:
gender, age group, race, smoking, CHF, hypertension, diabetes,
CAD, vascular disease, dementia, moderate-to-severe CKD, non-
steroidal anti-inﬂammatory drug (NSAID) usage, history of
bleeding, previous stroke/transient ischaemic attack (TIA)/sys-
temic embolism (SE), and cohort. Multiple Imputation by
Chained Equations (MICE) was used to ﬁll in missing values,
creating ﬁve complete datasets.16 17 First-degree interaction
between baseline characteristics and time (cohort) or between
comorbidities and time (cohort) were tested using likelihood
ratio tests. Only signiﬁcant interactions were included in the
ﬁnal model.
Both SAS V.9.4 (SAS Institute Inc, Cary, North Carolina,
USA) and Stata Statistical Software: Release 14 (StataCorp,
College Station, Texas, USA) were used for the data analysis.
RESULTS
Study population
Between March 2010 and July 2015, 39 670 patients were
enrolled in four sequential cohorts: C1 (2010–2011), n=5500;
C2 (2011–2013), n=11 662; C3 (2013–2014), n=11 462; C4
(2014–2015), n=11 046. Baseline characteristics across the four
cohorts were similar, although C3 and C4 had a slightly lower
prevalence of prior stroke/TIA (table 1).
Antithrombotic therapy use by cohort
Figure 1 shows the prescribing patterns at diagnosis of AF in all
four cohorts. The proportion of patients on AC therapy at diag-
nosis, with or without an antiplatelet (AP) agent, increased from
C1 to C4. This rise was due to increasing use of NOACs, with
or without AP, and was greater for FXaIs than for DTI. At the
same time, there was a decline in the use of VKA, with or
without AP, as well as AP therapy alone, while the proportion of
patients not receiving antithrombotic therapy remained
unchanged. Table 2 shows the baseline characteristics for all
patients by treatment group. Patients receiving no treatment
were generally younger and healthier, with a lower incidence of
comorbidities, and had lower CHA2DS2-VASc and HAS-BLED
scores.
Table 3 shows the baseline characteristics of patients on NOACs
by cohort. Patients treated early after the introduction of NOACs
(C1) were more likely than those in later cohorts to suffer from
signiﬁcant underlying disease such as CAD, vascular disease, CKD,
Table 3 Baseline characteristics of patients on NOACs by cohort
Variable Cohort 1 2010–2011 Cohort 2 2011–2013 Cohort 3 2013–2014 Cohort 4 2014–2015
N 224 1611 3000 4065
Female, n (%) 102 (45.5) 703 (43.6) 1351 (45.0) 1767 (43.5)
Age at diagnosis, years, mean (SD) 70.9 (12.5) 70.5 (11.1) 70.8 (10.7) 70.9 (10.7)
Medical history, n (%)
CAD 62 (27.7) 254 (15.8) 518 (17.3) 731 (18.0)
Vascular disease 59 (26.3) 187 (11.6) 381 (12.7) 587 (14.4)
Systemic embolism 2 (0.9) 15 (0.9) 12 (0.4) 29 (0.7)
Stroke 19 (8.5) 163 (10.1) 190 (6.3) 314 (7.7)
Bleeding 13 (5.8) 32 (2.0) 56 (1.9) 86 (2.1)
Hypertension 175 (78.1) 1316 (81.7) 2464 (82.1) 3279 (80.7)
Diabetes mellitus 61 (27.2) 321 (19.9) 614 (20.5) 850 (20.9)
Moderate-to-severe CKD* 40 (17.9) 158 (9.8) 307 (10.2) 380 (9.3)
Risk scores
CHA2DS2-VASc, median (Q1–Q3) 4.0 (2.0–5.0)
a 3.0 (2.0–4.0)b 3.0 (2.0–4.0)c 3.0 (2.0–4.0)d
CHA2DS2-VASc, 0–1, n (%) 29 (13.0) 209 (13.2) 407 (13.8) 571 (14.2)
HAS-BLED, median (Q1–Q3)† 2.0 (1.0–2.0)e 1.0 (1.0–2.0)f 1.0 (1.0–2.0)g 1.0 (1.0–2.0)h
HAS-BLED, 0–2, n (%)† 130 (78.8) 956 (89.8) 2132 (92.2) 2964 (92.6)
a1 patient missing; b32 patients missing; c41 patients missing; d57 patients missing; e59 patients missing; f547 patients missing; g687 patients missing; h864 patients missing.
CAD, coronary artery disease; CHA2DS2-VASc, cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65–74 and sex category (female); CKD,
chronic kidney disease; NKF KDOQI, National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative; NOAC, non-vitamin K antagonist oral anticoagulant.
*Includes NKF KDOQI stages III–V.
†‘modified’ HAS-BLED, hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, elderly (>65), drugs/alcohol concomitantly (1 point each).
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and diabetes. Analysis of the baseline characteristics of 20 167
patients in the later cohorts (C2, C3, and C4) who were prescribed
either VKA or NOACs found that NOAC use was more frequent
than VKA use in men, patients of Asian ethnicity, the elderly,
patients with dementia, those using NSAIDs, and current smokers
(table 4). VKA use was more common in patients with cardiac, vas-
cular, or renal comorbidities.
Antithrombotic therapy use according to risk score
Use of antithrombotic therapy stratiﬁed by CHA2DS2-VASc
score and cohort is shown in ﬁgure 2. Regardless of cohort, the
proportion of patients on AC therapy increased with
CHA2DS2-VASc score. Although the highest levels of anticoagu-
lation were observed in patients with a CHA2DS2-VASc score
≥2, the increase in anticoagulation from C1 to C4 was greatest
in patients with a score of 0. NOAC prescribing increased
between C1 and C4 in all CHA2DS2-VASc score strata.
Stratifying treatment by HAS-BLED score (ﬁgure 3), the pro-
portion of patients on AC therapy decreased with increasing
score, especially beyond a score of 2. In contrast, higher
HAS-BLED scores were associated with a greater proportion of
patients on AP therapy alone or in combination with an AC. As
the HAS-BLED score increased, the proportion of patients on
no treatment rose.
DISCUSSION
Data from the GARFIELD-AF cohorts collected over the past
5 years show a pronounced change in the pattern of antithrom-
botic therapy prescribing in patients with newly diagnosed AF.
The use of AC therapy has increased and exceeds 70% in the
most recent cohort. This change is predominantly due to
increasing use of NOACs. Thromboprophylaxis with AP and
VKA therapies alone and in combination has declined.
This paradigm shift in prescribing practice has been driven in
part by the availability of NOACs, but also the realisation that
APs are barely effective compared with ACs. Evaluating the pro-
fessional society guidelines published over the last 5 years (espe-
cially relating to AP therapy),3 4 18–22 it is notable that the
Japanese guidelines, for example, no longer recommend AP for
stroke prevention in patients with AF. European Society of
Cardiology and National Institute for Health and Care
Excellence (NICE) guidelines also restrict the use of aspirin and
other AP therapies for patients who refuse anticoagulation.
American College of Cardiology/American Heart Association
and Canadian guidelines have curtailed their recommendations
on the use of these agents.4 21 22
Changes in AC therapy have occurred despite initial reluc-
tance on the part of healthcare payers due to the greater cost of
NOAC medication compared with VKA or AP therapy.
However, the evidence suggests that long-term therapy with
NOACs may be cost-effective compared with VKA treat-
ment,23 24 primarily due to lower monitoring costs and reduced
numbers of patients with strokes and SE.
CHA2DS2-VASc score analysis showed an increase in the use
of NOAC therapy at all levels of risk, including those patients
with a score of 0. While this may indicate some level of over-
treatment, it should be noted that the patients with AF recruited
into GARFIELD-AF were judged by their physician to have at
least one additional risk factor for stroke. Patients may also have
been prescribed ACs for transient purposes such as cardiover-
sion or AF ablation. HAS-BLED score analysis found that AC
prescribing diminished as bleeding risk increased, and a surpris-
ingly high frequency of AP therapy alone or combined with ACs
was still prescribed.
Notably, we have previously shown that there are no gender
differences in the treatment patterns of patients (in C1 and
C2).25 Patients treated early after the introduction of NOACs
(cohort C1) were more likely than those in later cohorts to
suffer from signiﬁcant underlying disease. Analysis of the later
cohorts found that NOACs were more frequently used than
VKAs in the elderly and in those with dementia or taking
NSAIDs, perhaps because of their ease of use and the perceived
lower bleeding risk. The preferential use of NOACs in patients
of Asian ethnicity may have been an attempt to lower the inci-
dence of intracranial haemorrhage. A higher frequency of
Table 4 Use of NOACs in relation to baseline characteristics for
patients on AC at baseline (n=20 167)
Variable OR‡ (95% CI)
Gender
Female 1
Male 1.08 (1.01 to 1.15)
Ethnicity
Caucasian/Hispanic/Latino 1
Asian 1.28 (1.19 to 1.37)
Other 1.08 (0.87 to 1.35)
Age, years
65 1
65–80 1.10 (1.02 to 1.18)
80–85 1.19 (1.08 to 1.32)
>85 1.32 (1.16 to 1.50)
Medical history*
CHF 0.94 (0.87 to 1.01)
Hypertension (history or >140/90 mm Hg) 0.90 (0.83 to 0.97)
Diabetes 0.82 (0.77 to 0.88)
CAD 0.85 (0.77 to 0.94)
Vascular disease 0.87 (0.79 to 0.97)
Dementia 1.46 (1.13 to 1.88)
Moderate-to-severe CKD† 0.84 (0.76 to 0.92)
NSAID usage 1.27 (1.06 to 1.53)
Bleeding 1.19 (0.96 to 1.48)
Smoking
Never 1
Ex-smoker 1.05 (0.98 to 1.13)
Current smoker 1.16 (1.05 to 1.29)
Previous stroke/TIA/SE (reference: no previous stroke/TIA/SE)
In cohort 2 (2011–2013) 1.08 (0.91 to 1.28)
In cohort 3 (2013–2014) 0.76 (0.65 to 0.89)
In cohort 4 (2014–2015) 0.95 (0.82 to 1.10)
Patients without stroke/TIA/SE
Cohort 2 (2011–2013) 1
Cohort 3 (2013–2014) 2.33 (2.14 to 2.53)
Cohort 4 (2014–2015) 3.82 (3.52 to 4.15)
Patients with previous stroke/TIA/SE
Cohort 2 (2011–2013) 1
Cohort 3 (2013–2014) 1.64 (1.32 to 2.03)
Cohort 4 (2014–2015) 3.37 (2.74 to 4.15)
*Reference group is patients with no medical history.
†Includes NKF KDOQI stages III to V; none or mild (reference group) includes all other
patients.
‡An OR >1 implies that NOACs are more frequent than VKAs, while an OR <1 means
that VKAs are more frequent than NOACs. Only the interaction between cohort and
stroke/TIA/SE was statistically significant (p=0.01).
AC, anticoagulant; CAD, coronary artery disease; CHF, congestive heart failure; CKD,
chronic kidney disease; NKF KDOQI, National Kidney Foundation’s Kidney Disease
Outcomes Quality Initiative; NOAC, non-vitamin K antagonist oral anticoagulant;
NSAID, non-steroidal anti-inflammatory drug; SE, systemic embolism; TIA, transient
ischaemic attack; VKA, vitamin K antagonist.
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patients with hypertension, CAD, and diabetes was prescribed
VKAs, possibly combined with AP therapy, since experience
with the combination of NOAC and AP is limited.26 Patients
with CKD were more likely to receive VKAs, presumably
because of the moderate-to-high dependency of NOACs on
renal elimination. It appears that, despite compelling evidence
for the use of NOACs in secondary prevention,27–30 prescribers
remain relatively wary of NOAC thromboprophylaxis in patients
with prior thromboembolic events, predominantly stroke.
The acceptance of AC therapy in AF among physicians is a
positive step. However, there has been no decrease in the pro-
portion of patients that receive no antithrombotic treatment,
which remains at about 10% of the population. This population
includes some patients at high thromboembolic risk, with low
HAS-BLED scores, for whom anticoagulation would seem to be
appropriate.
GARFIELD-AF provides a unique picture of prescribing at
the end of the VKA-only era, showing the global increase in
NOAC prescribing. Our ﬁndings are strengthened by protocol-
mandated source data veriﬁcation of 20% of eCRFs and central
monitoring, ensuring high data quality. A limitation of this
study is that only global patterns of antithrombotic therapy
were investigated. Regional differences in prescribing trends
were not taken into account, nor was the rate of NOAC
approvals across each region. Comorbidities were also likely
confounders, which were not fully assessed in this analysis.
CONCLUSION
Since the introduction of NOACs, newly diagnosed at-risk
patients with AF are more often receiving guideline-recom-
mended therapy, driven by increased use of NOACs and less
treatment with AP and VKA therapies.
Figure 2 Antithrombotic treatment at diagnosis by CHA2DS2-VASc score and cohort, for patients with a score of 0, 1, and ≥2. The total
population represented by n excludes unknowns. Patients with missing CHA2DS2-VASc score: C1 94; C2 369; C3 210; C4 216. AP, antiplatelet;
CHA2DS2-VASc, cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65–74 and sex category (female);
DTI, direct thrombin inhibitor; FXaI, factor Xa inhibitor; VKA, vitamin K antagonist.
Figure 3 Antithrombotic treatment
at diagnosis by HAS-BLED score,* for
patients with a score of 0, 1, 2, and
≥3, in all cohorts combined. The total
population represented by n excludes
unknowns. Patients with missing
HAS-BLED score: C1 1939; C2 4360;
C3 2878; C4 2392. AP, antiplatelet;
DTI, direct thrombin inhibitor; FXaI,
factor Xa inhibitor; *‘modiﬁed’ HAS-
BLED, hypertension, abnormal renal/
liver function (1 point each), stroke,
bleeding history or predisposition,
elderly (>65), drugs/alcohol
concomitantly (1 point each); VKA,
vitamin K antagonist.
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Key messages
What is already known on this subject?
Atrial ﬁbrillation (AF) is associated with a ﬁvefold increase in
stroke risk. Anticoagulant (AC) therapy is known to reduce this
risk in patients with AF, but evidence shows that it is
underutilised.
What might this study add?
In this large, global, observational study of patients with newly
diagnosed non-valvular AF and ≥1 additional risk factor for
stroke, we investigated prospectively the changing pattern of
antithrombotic therapy over the past 5 years, before and after
the introduction of non-vitamin K antagonist oral ACs (NOACs).
Since the introduction of NOACs, there has been an increase in
newly diagnosed patients with AF at risk of stroke receiving
guideline-recommended therapy, predominantly driven by
increased use of NOACs and reduced use of vitamin K
antagonists±antiplatelet therapy or antiplatelet therapy alone.
How might this impact on clinical practice?
The acceptance of AC therapy in AF among physicians is a
positive step. However, there has been no change in the
proportion of patients that receive no antithrombotic treatment,
including apparently eligible patients at high stroke risk and low
bleeding risk.
Author afﬁliations
1Division of Cardiovascular Sciences, St George’s University of London, London, UK
2Thrombosis Research Institute, London, UK
3Division of Cardiology, University of Perugia School of Medicine, Perugia, Italy
4Department of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway
5Faculty of Medicine, University of Oslo, Oslo, Norway
6Department of Cardiology, EA 3920, University of Besançon, Besançon, France
7Department of Internal Medicine, Oslo University Hospital, Oslo, Norway
8AZ Klina, Brasschaat, Belgium
9Department of Primary Care Clinical Sciences, University of Birmingham,
Birmingham, UK
10Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard
Medical School, Boston, USA
11Department of Medicine (Cardiology), Tokai University School of Medicine, Isehara,
Japan
12Formerly Haemostasis and Thrombosis Research Group, Institute for Experimental
Oncology and Therapy Research, Technical University Munich, Munich, Germany
13Institute for Clinical Research, National Hospital Organization, Osaka National
Hospital, Osaka, Japan
14Center for Public Health Research (CESP), University of Milano-Bicocca, Milan, Italy
15Bayer HealthCare Pharmaceuticals, Berlin, Germany
16Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
17Department of Medicine, McMaster University, Hamilton, Canada
18Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam,
The Netherlands
19Department of Surgery, University College London, London, UK
Acknowledgements We thank the physicians, nurses, and patients involved in
the GARFIELD-AF registry. We would also like to thank the following people who
were involved in the preparation of this manuscript: Bernard J Gersh (Mayo Medical
School, Rochester, USA) and Keith AA Fox (University of Edinburgh, Edinburgh, UK)
for their work in the audit of GARFIELD-AF data; Antonello Ciccarone (TRI, London,
UK), SAS programming support; Claire Aukim-Hastie, Emily Chu, and Rae Hobbs
(TRI, London, UK), medical writing support.
Collaborators The full list of GARFIELD-AF Investigators are listed in an online
supplementary ﬁle which is available with this article.
Contributors AJC, J-PB, DAF, SZG, SG, SH, GK, LGM, FM, AGGT, FWAV, and AKK
contributed to the study design. GAm, DA, EB, FC, SZG, YK, and SO contributed to
data acquisition. GAc analysed the data. All authors contributed to data
interpretation. AJC drafted the report. All authors critically reviewed the report and
approved the ﬁnal manuscript.
Funding The GARFIELD-AF registry is sponsored by the TRI, London, UK, and is
supported by an unrestricted research grant from Bayer Pharma AG, Berlin, Germany
(AKK). The funding source had no involvement in the data collection, data analysis,
or data interpretation.
Competing interests AJC: advisor to Bayer, Boehringer Ingelheim, Pﬁzer/BMS,
and Daiichi Sankyo. GAm: advisor to Merck, Menarini, and Angelini. DA: personal
fees from Bayer Healthcare, BMS/Pﬁzer, Boehringer-Ingelheim, and MSD. J-PB:
personal fees from Aspen. FC: personal fees from Bayer, BMS, and
Boehringer-Ingelheim. DAF: personal fees from BMS/Pﬁzer, Boehringer-Ingelheim,
Daiichi Sankyo, and Bayer. SZG: grants from BiO2 Medical, Boehringer-Ingelheim,
Bristol Meyers Squibb, BTG EKOS, Daiichi Sankyo, National Heart Lung and Blood
Institute of the National Institutes of Health, Janssen, and Thrombosis Research
Group; personal fees from Bayer, Boehringer-Ingelheim, Bristol Meyers Squibb,
Daiichi Sankyo, Janssen, and Portola. SG: personal fees from the TRI, Bayer, and
AstraZeneca; grants from Sanoﬁ and Pﬁzer. SH: personal fees from Aspen, Bayer
Healthcare, BMS/Pﬁzer, Daiichi-Sankyo, and Sanoﬁ. YK: grants and personal fees
from Daiichi Sankyo and Boehringer-Ingelheim; personal fees from Bayer,
Bristol-Meyers Squibb, and Pﬁzer. LGM: grants and personal fees from Bayer
Healthcare and Pﬁzer; grants from Boehringer Ingelheim; personal fees from Daiichi
Sankyo. FM: employee of Bayer Pharma AG. SO: consultant/advisory board
payments from Bayer Pharma AG, Bristol-Myers Squibb Korea, Boehringer-Ingelheim
Korea, Pﬁzer Korea, Sanoﬁ-Aventis, and St Jude Medical. AGGT: personal fees from
Bayer Healthcare, Janssen Pharmaceutical Research & Development LLC, Astellas,
Portola, and Takeda. FWAV: personal fees from Bayer Healthcare, Daiichi-Sankyo,
BMS/Pﬁzer, and Boehringer-Ingelheim. AKK: grants and personal fees from Bayer
Healthcare; personal fees from Boehringer-Ingelheim Pharma, Daiichi Sankyo Europe,
Sanoﬁ SA, Janssen.
Patient consent Obtained.
Ethics approval Independent ethics committees and hospital-based institutional
review boards.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
REFERENCES
1 Wolf PA, Abbott RD, Kannel WB. Atrial ﬁbrillation as an independent risk factor for
stroke: the Framingham Study. Stroke 1991;22:983–8.
2 Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial ﬁbrillation. The
Framingham Study. Stroke 1996;27:1760–4.
3 Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC
Guidelines for the management of atrial ﬁbrillation: an update of the 2010 ESC
Guidelines for the management of atrial ﬁbrillation. Developed with the special
contribution of the European Heart Rhythm Association. Eur Heart J
2012;33:2719–47.
4 January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the
management of patients with atrial ﬁbrillation: a report of the American College of
Cardiology/American Heart Association Task Force on practice guidelines and the
Heart Rhythm Society. Circulation 2014;130:e199–267.
5 Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the Canadian
Cardiovascular Society atrial ﬁbrillation guidelines: recommendations for
stroke prevention and rate/rhythm control. Can J Cardiol 2012;28:
125–36.
6 Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial
ﬁbrillation: a systematic review. Am J Med 2010;123:638–45.e4.
7 Goto S, Bhatt DL, Röther J, et al. Prevalence, clinical proﬁle, and cardiovascular
outcomes of atrial ﬁbrillation patients with atherothrombosis. Am Heart J
2008;156:855–63, 863.e2.
8 Atarashi H, Inoue H, Okumura K, et al. Present status of anticoagulation treatment
in Japanese patients with atrial ﬁbrillation: a report from the J-RHYTHM Registry.
Circ J 2011;75:1328–33.
9 Lopes RD, Shah BR, Olson DM, et al. Antithrombotic therapy use at discharge and
1 year in patients with atrial ﬁbrillation and acute stroke: results from the AVAIL
Registry. Stroke 2011;42:3477–83.
10 Mahmud A, Bennett K, Okechukwu I, et al. National underuse of anti-thrombotic
therapy in chronic atrial ﬁbrillation identiﬁed from digoxin prescribing. Br J Clin
Pharmacol 2007;64:706–9.
11 Nieuwlaat R, Capucci A, Lip GY, et al. Antithrombotic treatment in real-life atrial
ﬁbrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur
Heart J 2006;27:3018–26.
Camm AJ, et al. Heart 2016;0:1–8. doi:10.1136/heartjnl-2016-309832 7
Arrhythmias and sudden death
group.bmj.com on October 6, 2016 - Published by http://heart.bmj.com/Downloaded from 
12 Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of
patients with atrial ﬁbrillation at risk of stroke: Global Anticoagulant Registry in the
FIELD (GARFIELD). Am Heart J 2012;163:13–19.e1.
13 National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney
disease: evaluation, classiﬁcation, and stratiﬁcation. Am J Kidney Dis 2002;39(Suppl
1):S1–266.
14 Lip GY, Nieuwlaat R, Pisters R, et al. Reﬁning clinical risk stratiﬁcation for predicting
stroke and thromboembolism in atrial ﬁbrillation using a novel risk factor-based
approach: the Euro Heart Survey on atrial ﬁbrillation. Chest 2010;137:263–72.
15 Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to
assess 1-year risk of major bleeding in patients with atrial ﬁbrillation: the Euro
Heart Survey. Chest 2010;138:1093–100.
16 van Buuren S. Multiple imputation of discrete and continuous data by fully
conditional speciﬁcation. Stat Methods Med Res 2007;16:219–42.
17 Raghunathan TE, Lepkowski JM, Van Hoewyk J, et al. A multivariate technique for
multiply imputing missing values using a sequence of regression models. Survey
Methodol 2001;85:85–95.
18 Ogawa S, Aonuma K, Tse HF, et al. The APHRS’s 2013 statement on antithrombotic
therapy of patients with nonvalvular atrial ﬁbrillation. J Arrhythm
2013;29:190–200.
19 You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial ﬁbrillation:
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of
Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:
e531S–75S.
20 JCS Joint Working Group. Guidelines for pharmacotherapy of atrial ﬁbrillation ( JCS
2008): digest version. Circ J 2010;74:2479–500.
21 Cairns JA, Connolly S, McMurtry S, et al. Canadian Cardiovascular Society atrial
ﬁbrillation guidelines 2010: prevention of stroke and systemic thromboembolism in
atrial ﬁbrillation and ﬂutter. Can J Cardiol 2011;27:74–90.
22 Verma A, Cairns JA, Mitchell LB, et al. 2014 focused update of the Canadian
Cardiovascular Society guidelines for the management of atrial ﬁbrillation. Can
J Cardiol 2014;30:1114–30.
23 Shields GE, Bates AE, Chapman AM. Implementing guidelines: the cost and clinical
impact of anticoagulants in the UK atrial ﬁbrillation population. Appl Health Econ
Health Policy 2015;13:543–51.
24 Vestergaard AS, Ehlers LH. A health economic evaluation of stroke prevention in
atrial ﬁbrillation: guideline adherence versus the observed treatment strategy prior to
2012 in Denmark. Pharmacoeconomics 2015;33:967–79.
25 Lip GY, Rushton-Smith SK, Goldhaber SZ, et al. Does sex affect anticoagulant use
for stroke prevention in nonvalvular atrial ﬁbrillation?: the prospective global
anticoagulant registry in the FIELD-Atrial Fibrillation. Circ Cardiovasc Qual Outcomes
2015;8:S12–20.
26 Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy
with dabigatran or warfarin in the Randomized Evaluation of Long-Term
Anticoagulation Therapy (RE-LY) trial. Circulation 2013;127:634–40.
27 Diener HC, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in
patients with atrial ﬁbrillation and previous transient ischaemic attack or stroke: a
subgroup analysis of the RE-LY trial. Lancet Neurol 2010;9:1157–63.
28 Diener HC, Eikelboom J, Connolly SJ, et al. Apixaban versus aspirin in patients with
atrial ﬁbrillation and previous stroke or transient ischaemic attack: a predeﬁned
subgroup analysis from AVERROES, a randomised trial. Lancet Neurol
2012;11:225–31.
29 Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients
with atrial ﬁbrillation and previous stroke or transient ischaemic attack: a subgroup
analysis of the ARISTOTLE trial. Lancet Neurol 2012;11:503–11.
30 Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban compared with warfarin in
patients with atrial ﬁbrillation and previous stroke or transient ischaemic attack: a
subgroup analysis of ROCKET AF. Lancet Neurol 2012;11:315–22.
8 Camm AJ, et al. Heart 2016;0:1–8. doi:10.1136/heartjnl-2016-309832
Arrhythmias and sudden death
group.bmj.com on October 6, 2016 - Published by http://heart.bmj.com/Downloaded from 
fibrillation
for patients with newly diagnosed atrial 
Evolving antithrombotic treatment patterns
G Turpie, Freek W A Verheugt and Ajay K Kakkar
GKoretsune, Lorenzo G Mantovani, Frank Misselwitz, Seil Oh, Alexander 
Samuel Z Goldhaber, Shinya Goto, Sylvia Haas, Gloria Kayani, Yukihiro
Jean-Pierre Bassand, Eivind Berge, Frank Cools, David A Fitzmaurice, 
A John Camm, Gabriele Accetta, Giuseppe Ambrosio, Dan Atar,
 published online September 19, 2016Heart 
 http://heart.bmj.com/content/early/2016/09/19/heartjnl-2016-309832
Updated information and services can be found at: 
These include:
References
 #BIBL
http://heart.bmj.com/content/early/2016/09/19/heartjnl-2016-309832
This article cites 30 articles, 9 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (631)Tobacco use
 (2984)Hypertension
 (8791)Drugs: cardiovascular system
 (195)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on October 6, 2016 - Published by http://heart.bmj.com/Downloaded from 
